CYPROHEPTADINE HCL EFFECT ON FAILURE TO THRIVE

盐酸赛庚啶对生长失败的影响

• 批准号: 6122623
• 负责人: MICHAEL KAPLAN
• 金额: $ 2.58万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122623
• 关键词: body weight; chemotherapy; clinical research; clinical trials; cyproheptadine; drug screening /evaluation; family structure /dynamics; human subject; human therapy evaluation; infant human (0-1 year); pediatric pharmacology; postnatal growth disorder; socioenvironment

Children with nonorganic failure to thrive present a difficult challenge to the pediatrician as there is no specific treatment once organic etiologies have been ruled out. This study is investigating whether Cyproheptadine HCL (Periactin), an antihistamine with appetite stimulating effects, will promote weight gain in children with nonorganic failure to thrive. Weight gain in these children will be evaluated to determine if it is due to a physiological effect of the medication or to an improvement in psychsocial functioning in the family.

非器质性发育不良的儿童对儿科医生来说是一个困难的挑战，因为一旦排除了器质性病因，就没有具体的治疗方法。 本研究旨在调查盐酸赛庚啶（Periactin），一种具有食欲刺激作用的抗组胺药，是否会促进非器质性发育不良儿童的体重增加。 将对这些儿童的体重增加进行评估，以确定其是否是由于药物的生理作用或家庭心理社会功能的改善。